๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma

โœ Scribed by Fumihiko Kanai; Haruhiko Yoshida; Ryosuke Tateishi; Shinpei Sato; Takao Kawabe; Shuntaro Obi; Yuji Kondo; Makoto Taniguchi; Kazumi Tagawa; Masafumi Ikeda; Chigusa Morizane; Takuji Okusaka; Hitoshi Arioka; Shuichiro Shiina; Masao Omata

Book ID
105993445
Publisher
Springer
Year
2010
Tongue
English
Weight
408 KB
Volume
67
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A phase II trial of gemcitabine in patie
A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma
โœ Charles S. Fuchs; Jeffrey W. Clark; David P. Ryan; Mathew H. Kulke; Haesook Kim; ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 74 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND There is no effective systemic therapy for patients with hepatocellular carcinoma. A recent trial reported a moderate antitumor activity for gemcitabine among Asian patients with advanced hepatocellular carcinoma. This led to our examination of the efficacy and tolerabili

A Phase II trial of nolatrexed dihydroch
A Phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma
โœ Keith Stuart; Judy Tessitore; Jeff Rudy; Neil Clendennin; Amanda Johnston ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 70 KB ๐Ÿ‘ 2 views

## BACKGROUND. Inoperable hepatocellular carcinoma is an incurable malignancy with no accepted standard therapy. Chemotherapy has demonstrated occasional responses and the need is great for a new and effective agent. Therefore the authors conducted this Phase II trial of a novel thymidylate syntha

Thalidomide in the treatment of patients
Thalidomide in the treatment of patients with hepatocellular carcinoma : A Phase II trial
โœ Yehuda Z. Patt; Manal M. Hassan; Richard D. Lozano; Ajay K. Nooka; Isaac I. Schn ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 91 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND The treatment of patients with hepatocellular carcinoma (HCC) presents a major challenge, because associated cirrhosis limits the choice of chemotherapeutic agents. However, the abundant vascularity of HCC presents an attractive target for antiangiogenic therapy that pote